RFS was significantly shorter in the high-risk group, with a tumor size ≥50 mm and an EMVI score of 4. The site of postoperative recurrence in the high-risk group was distant in all cases. In this group, CRT alone may be insufficient as neoadjuvant therapy to control distant recurrence.